Clinical Trial Update: A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Efepoetin Alfa for anemia in patients with chronic kidney disease on dialysis is currently recruiting. The sponsor is Genexine, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia of Chronic Kidney Disease

Drugs mentioned

• Efepoetin Alfa (Efepoetin alfa)

Snippet

Sponsor: Genexine, Inc. | Conditions: Anemia of Chronic Kidney Disease | Phase 3 | Status: RECRUITING